BMRA · Insider Trading
BIOMERICA INC
Every open-market purchase and sale reported by BMRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | M. Huff Gary | Director | Buy | +31,250 | +$50.00K |
| 2026-08-27 | Allen Barbieri | Executive Vice Chairman | Buy | +20,000 | +$32.00K |
| 2026-08-27 | David Moatazedi | Director | Buy | +10,000 | +$16.00K |
| 2026-08-27 | Zackary S. Irani | Chief Executive Officer | Buy | +31,250 | +$50.00K |
| 2026-08-27 | Eric Chin | Director | Buy | +6,250 | +$10.00K |
| 2026-01-28 | Eric Chin | Director | A | +22,500 | — |
| 2025-12-31 | Gary Lu | Chief Financial Officer | A | +40,000 | — |
| 2025-12-31 | M. Huff Gary | Director | A | +20,000 | — |
| 2025-12-31 | Zackary S. Irani | Chief Executive Officer | A | +52,500 | — |
| 2025-12-31 | Allen Barbieri | Executive Vice-Chairman | A | +30,000 | — |
| 2025-12-31 | David Moatazedi | Director | A | +20,000 | — |
| 2024-12-17 | David Moatazedi | Director | A | +85,000 | +$26.35K |
| 2024-12-17 | Jane Emerson | Director | A | +85,000 | +$26.35K |
| 2024-12-17 | Catherine Coste | Director | A | +85,000 | +$26.35K |
| 2024-12-17 | Allen Barbieri | Executive Vice Chairman | A | +110,000 | +$34.10K |
| 2024-12-17 | Gary Lu | Chief Financial Officer | A | +155,000 | +$48.05K |
| 2024-12-17 | Zackary S. Irani | Chief Executive Officer | A | +250,000 | +$77.50K |
| 2023-12-14 | Catherine Coste | Director | A | — | — |
| 2023-12-14 | Zackary S. Irani | Chief Executive Officer | A | — | — |
| 2023-12-14 | John P. Kenny | Director | A | — | — |
| 2023-12-14 | Gary Lu | Chief Financial Officer | A | — | — |
| 2023-12-14 | David Moatazedi | Director | A | — | — |
| 2023-12-14 | Allen Barbieri | Executive Vice Chairman | A | — | — |
| 2023-12-14 | Jane Emerson | Director | A | — | — |
| 2023-12-11 | John P. Kenny | Director | A | — | — |
| 2023-12-11 | Catherine Coste | Director | A | — | — |
| 2023-12-11 | Allen Barbieri | Vice Chairman | A | — | — |
| 2023-12-11 | Jane Emerson | Director | A | — | — |
| 2023-12-11 | David Moatazedi | Director | A | — | — |
| 2023-12-11 | Zackary S. Irani | Chief Executive Officer | A | — | — |
| 2023-05-26 | Zackary S. Irani | Chief Executive Officer | Buy | +700 | +$1.11K |
| 2023-05-12 | Zackary S. Irani | Chief Executive Officer | Buy | +1,700 | +$1.99K |
| 2023-05-12 | Zackary S. Irani | Chief Executive Officer | Buy | +500 | +$635 |
| 2023-05-10 | Zackary S. Irani | Chief Executive Officer | Buy | +300 | +$417 |
| 2023-05-05 | Zackary S. Irani | Chief Executive Officer | Buy | +1,000 | +$1.36K |
| 2023-05-01 | Zackary S. Irani | Chief Executive Officer | Buy | +4,400 | +$5.82K |
| 2023-04-27 | Zackary S. Irani | Chief Executive Officer | Buy | +7,000 | +$8.82K |
| 2023-04-10 | Gary Lu | Chief Financial Officer | A | +100,000 deriv. | — |
| 2023-01-31 | Allen Barbieri | Executive Vice Chairman | Buy | +1,538 | +$4.52K |
| 2023-01-30 | Catherine Coste | Director | Buy | +2,190 | +$6.48K |
| 2023-01-26 | Zackary S. Irani | Chief Executive Officer | Buy | +1,800 | +$5.13K |
| 2023-01-25 | Zackary S. Irani | Chief Executive Officer | Buy | +2,000 | +$5.62K |
| 2021-12-10 | Steven Sloan | Chief Financial Officer | A | +40,000 deriv. | — |
| 2021-12-10 | Allen Barbieri | Director | A | — | — |
| 2021-12-10 | Catherine Coste | Director | A | — | — |
| 2021-12-10 | Jane Emerson | Director | A | — | — |
| 2021-12-10 | Zackary S. Irani | Chief Executive Officer | A | — | — |
| 2021-12-10 | Mark A Sirgo | Director | A | — | — |
| 2020-12-11 | Catherine Coste | Director | A | — | — |
| 2020-12-11 | Steven Sloan | Chief Financial Officer | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Zackary S. Irani | Chief Executive Officer | 242,570 | $414.79K |
| Allen Barbieri | Executive Vice Chairman | 73,542 | $125.76K |
| Gary Lu | Chief Financial Officer | 59,375 | $101.53K |
| M. Huff Gary | Director | 51,250 | $87.64K |
| David Moatazedi | Director | 40,625 | $69.47K |
| Eric Chin | Director | 38,750 | $66.26K |
| Jane Emerson | Director | 19,500 | $33.34K |
| Catherine Coste | Director | 17,237 | $29.48K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.